Subsequently we extended our investigation to 246 IPAH patients without and 65 with cardiopulmonary comorbidities who received genetic diagnostic PAH-gene panel testing within the same time frame to screen for SMAD6 variants of interest (Table 1). Here, SMAD6 is linked to idiopathic pulmonary arterial hypertension.